TenQ · fact sheet · filings current to · price as of
Abbott Laboratories (ABT)
A mixed picture - strengths and real weaknesses - 21 of 36 checks passed.
Latest close : $108.33, -0.4% on the day; -18.9% from the 52-week high. Refreshed every trading night.
Full analysis: report · all charts. Financial statements are computed from SEC EDGAR XBRL filings, current to . The share price and everything built on it (market cap, multiples, yields, the Value and Trend checks) are refreshed every trading night; this page shows the close of . Not investment advice.
Key figures
| Share price (delayed close) | $108.33 |
| Market cap | $188.7B |
| 52-week range | $81.98 - $133.53 |
| P/E | 30.2x |
| P/E, own 11-year median | 33.8x |
| P/S | 4.2x |
| Free cash flow yield | 3.9% |
| Dividend yield | 2.2% |
| Revenue (TTM) | $45.1B |
| Net income (TTM) | $6.3B |
| Free cash flow (TTM) | $7.4B |
| Gross margin | 37.1% |
| Operating margin | 17.1% |
| Return on equity | 12.1% |
| Revenue growth (1y) | +6.6% |
| Revenue CAGR (3y) | +0.5% |
| Debt / equity | 0.65x |
| Cash & short-term investments | $7.3B |
| Shares outstanding | 1,741.8m (cover page of the latest filing, 2026-03-31) |
The score: 21 of 36 checks passed
Six chapters, six pass/fail checks each. Five are computed from the filings; Trend is price behaviour, and says so.
Is ABT stock cheap or expensive right now?
Value · 1 of 6 checks passed. Expensive against its own history and its sector - you're paying up for what you get. chapter →
Is Abbott Laboratories still growing?
Growth · 2 of 6 checks passed. Growth is weak or inconsistent - the trend, not the story, is the problem. chapter →
Does Abbott Laboratories make real money?
Quality · 4 of 6 checks passed. A solidly profitable business, though not exceptional against its sector. chapter →
Can Abbott Laboratories survive a bad year?
Health · 4 of 6 checks passed. Financially sound overall, with one or two things worth watching. chapter →
What does Abbott Laboratories hand back to shareholders?
Shareholder returns · 6 of 6 checks passed. Owners are paid reliably and affordably, and the share count is not eroding their stake. chapter →
Which way is ABT trending?
Trend analysis · 4 of 6 checks passed. Mixed signals from the market - some trends up, some rolling over. chapter →
Are insiders buying or selling ABT?
Open-market buys: $1M · sells: $47M, across the recent Form 4 filings. detail →
Other pharma and chemicals we cover: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · Procter & Gamble (PG) · Amgen (AMGN) · every company →
Method: figures computed deterministically from SEC EDGAR XBRL (companyfacts, frames, financial-statement-and-notes datasets, Form 4); prices delayed end-of-day. Scores count transparent pass/fail checks. Missing data is shown as missing, never estimated. Last changed . © TenQ - cite with a link to this page.